

Global Drug modeling software Market - Industry Trends and Forecast to 2030

Market Report | 2023-06-01 | 468 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$4800.00
- Corporate Users License \$7000.00

Report description:

The drug modeling software market is expected to reach USD 16,808.81 million by 2030 from USD 8,504.35 million in 2022, growing at a CAGR of 9.2% during the forecast period of 2023 to 2033.

Market Segmentation:

Global Drug Modeling Software Market, By Component (Software, and Services), Operating System (Windows, Linux, Mac OS, and Others), Deployment Mode (Cloud Based, Hybrid Based, and On Premises), Enterprise Size(Large Enterprise Size, Small and Medium Enterprise Size), Application (Graphical Molecular Modeling, Gene Sequence Analysis, Protein Modeling, Modeling Crystal Structures, Cheminformatics, High Throughput Virtual Screening, Gas and Solution Phase Reaction, Medical Imaging, and Others), Purchase Model (Subscription Based, and One- Time License), End User(Pharmaceutical and Biotechnology Companies, Contract Research Organization, Research Institutes, Regulatory Authorities, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium, Poland, Sweden, Denmark, Finland, Norway, Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, Vietnam, Taiwan, Rest Of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Oman, Bahrain, Kuwait, Qatar, Rest of Middle East and Africa-Industry Trends and Forecast to 2030

Overview of Global Drug Modeling Software Market Dynamics :

Driver

- Rising drug discovery and development activities

Restrain

- Lack of quality data base

Opportunity

- Cloud computing and big data analytics in drug modelling

Scotts International. EU Vat number: PL 6772247784

Market Players:

The key market players operating in the drug modeling software market are listed below:

- Dotmatics
- BC Platforms
- InSilicoTrials Technologies.
- VeriSIM Life., Atomwise Inc.
- Certara, USA.
- GENECODE
- Cresset., and Nanome Inc.
- SIMULATIONS PLUS.
- Dassault Systemes
- Scripps Research
- XtalPi Inc.
- Xybion
- ArgusLab
- Schrodinger, Inc.

Table of Contents:

TABLE OF CONTENTS

- 1 INTRODUCTION 58
- 1.1 OBJECTIVES OF THE STUDY 58
- 1.2 MARKET DEFINITION 58
- 1.3 OVERVIEW OF THE GLOBAL DRUG MODELING SOFTWARE MARKET 58
- 1.4 CURRENCY AND PRICING 60
- 1.5 LIMITATIONS 60
- 1.6 MARKETS COVERED 60
- 2 MARKET SEGMENTATION 63
- 2.1 MARKETS COVERED 63
- 2.2 GEOGRAPHICAL SCOPE 64
- 2.3 YEARS CONSIDERED FOR THE STUDY 65
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 66
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 69
- 2.6 MULTIVARIATE MODELING 70
- 2.7 COMPONENT LIFELINE CURVE 70
- 2.8 DBMR MARKET POSITION GRID 71
- 2.9 VENDOR SHARE ANALYSIS 72
- 2.10 MARKET APPLICATION COVERAGE GRID 73
- 2.11 SECONDARY SOURCES 74
- 2.12 ASSUMPTIONS 74
- **3 EXECUTIVE SUMMARY 75**
- 3.1 PORTER'S FIVE FORCES MODEL 81
- 3.2 VALUE CHAIN ANALYSIS 82
- 3.3 REGULATORY STANDARDS 83

Scotts International. EU Vat number: PL 6772247784

- 3.4 TECHNOLOGICAL TRENDS 84
- 3.5 BENEFITS OF DRUG MODELING SOFTWARE 85
- 4 MARKET OVERVIEW 86
- **4.1 DRIVERS 88**
- 4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 88
- 4.1.2 RISING DEMAND FOR NOVEL THERAPIES 90
- 4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 91
- 4.2 RESTRAINTS 92
- 4.2.1 LACK OF QUALITY DATA BASE 92
- 4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 92
- 4.3 OPPORTUNITIES 93
- 4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 93
- 4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 94
- 4.4 CHALLENGES 94
- 4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 94
- 4.4.2 CHALLENGES WITH MODEL INTERPRETATION 95
- 5 GLOBAL DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 96
- 5.1 OVERVIEW 97
- 5.1.1 SOFTWARE 100
- 5.1.1.1 INTEGRATED 101
- 5.1.1.2 STANDALONE 101
- 5.1.1.3 LIGAND BASED 101
- 5.1.1.4 STRUCTURE BASED 101
- **5.2 SERVICES 101**
- 5.2.1 PROFESSIONAL SERVICES 102
- 5.2.1.1 CONSULTING AND TRAINING 103
- 5.2.1.2 INTEGRATION AND IMPLEMENTATION 103
- 5.2.1.3 SUPPORT AND MAINTENANCE 103
- 5.2.2 MANAGED SERVICES 103
- 6 GLOBAL DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 104
- 6.1 OVERVIEW 105
- 6.2 WINDOWS 108
- 6.3 LINUX 108
- 6.4 MAC OS 109
- 6.5 OTHERS 110
- 7 GLOBAL DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 111
- **7.1 OVERVIEW 112**
- 7.2 CLOUD BASED 115
- 7.3 HYBRID-BASED 115
- 7.4 ON-PREMISES 116
- 8 GLOBAL DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 117
- **8.1 OVERVIEW 118**
- 8.2 LARGE ENTERPRISE SIZE 121
- 8.3 SMALL & MEDIUM ENTERPRISE SIZE 121
- 9 GLOBAL DRUG MODELING SOFTWARE MARKET, BY APPLICATION 123
- 9.1 OVERVIEW 124
- 9.2 GRAPHICAL MOLECULAR MODELING 127

- 9.3 GENE SEQUENCE ANALYSIS 127
- 9.4 PROTEIN MODELING 128
- 9.5 MODELING CRYSTAL STRUCTURES 129
- 9.6 CHEMINFORMATICS 130
- 9.7 HIGH THROUGHPUT VIRTUAL SCREENING 131
- 9.8 GAS & SOLUTION PHASE REACTION 131
- 9.9 MEDICAL IMAGING 132
- 9.10 OTHERS 133
- 10 GLOBAL DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 134
- 10.1 OVERVIEW 135
- 10.2 SUBSCRIPTION BASED 138
- 10.2.1 ANNUALLY SUBSCRIPTION 139
- 10.2.2 MONTHLY SUBSCRIPTION 139
- 10.3 ONE-TIME LICENSE 139
- 10.3.1 GROUP LICENSE 140
- 10.3.2 DESKTOP LICENSE 140
- 10.3.3 OTHERS 140
- 11 GLOBAL DRUG MODELING SOFTWARE MARKET, BY END USER 141
- 11.1 OVERVIEW 142
- 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 145
- 11.2.1 LARGE ENTERPRISE SIZE 146
- 11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 146
- 11.3 CONTRACT RESEARCH ORGANIZATIONS 146
- 11.3.1 LARGE ENTERPRISE SIZE 147
- 11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 147
- 11.4 RESEARCH INSTITUTES 147
- 11.4.1 LARGE ENTERPRISE SIZE 148
- 11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 148
- 11.5 REGULATORY AUTHORITIES 148
- 11.5.1 LARGE ENTERPRISE SIZE 149
- 11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 150
- 11.6 OTHERS 150
- 11.6.1 LARGE ENTERPRISE SIZE 151
- 11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 151
- 12 GLOBAL DRUG MODELING SOFTWARE MARKET, BY REGION 152
- 12.1 OVERVIEW 153
- 12.2 NORTH AMERICA 159
- 12.2.1 U.S. 169
- 12.2.2 CANADA 174
- 12.2.3 MEXICO 179
- 12.3 EUROPE 184
- 12.3.1 GERMANY 195
- 12.3.2 FRANCE 200
- 12.3.3 U.K. 205
- 12.3.4 ITALY 210
- 12.3.5 RUSSIA 215
- 12.3.6 SPAIN 220

- 12.3.7 TURKEY 225
- 12.3.8 NETHERLANDS 230
- 12.3.9 SWITZERLAND 235
- 12.3.10 BELGIUM 240
- 12.3.11 POLAND 245
- 12.3.12 SWEDEN 250
- 12.3.13 DENMARK 255
- 12.3.14 FINLAND 260
- 12.3.15 NORWAY 265
- 12.3.16 REST OF EUROPE 270
- 12.4 ASIA-PACIFIC 271
- 12.4.1 CHINA 282
- 12.4.2 JAPAN 287
- 12.4.3 SOUTH KOREA 292
- 12.4.4 INDIA 297
- 12.4.5 AUSTRALIA 302
- 12.4.6 SINGAPORE 307
- 12.4.7 THAILAND 312
- 12.4.8 INDONESIA 317
- 12.4.9 PHILIPPINES 322
- 12.4.10 MALAYSIA 327
- 12.4.11 NEW ZEALAND 332
- 12.4.12 VIETNAM 337
- 12.4.13 TAIWAN 342
- 12.4.14 REST OF ASIA-PACIFIC 347
- 12.5 SOUTH AMERICA 348
- 12.5.1 BRAZIL 359
- 12.5.2 ARGENTINA 364
- 12.5.3 REST OF SOUTH AMERICA 369
- 12.6 MIDDLE EAST AND AFRICA 370
- 12.6.1 SOUTH AFRICA 380
- 12.6.2 SAUDI ARABIA 385
- 12.6.3 U.A.E. 390
- 12.6.4 EGYPT 395
- 12.6.5 ISRAEL 400
- 12.6.6 OMAN 405
- 12.6.7 BAHRAIN 410
- 12.6.8 KUWAIT 415
- 12.6.9 QATAR 420
- 12.6.10 REST OF MIDDLE EAST AND AFRICA 425
- 13 GLOBAL DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 426
- 13.1 COMPANY SHARE ANALYSIS: GLOBAL 426
- 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 427
- 13.3 COMPANY SHARE ANALYSIS: EUROPE 428
- 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 429
- 14 SWOT ANALYSIS 430
- 15 GLOBAL DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 431

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1 DASSAULT SYSTEMES 431
- 15.1.1 COMPANY SNAPSHOT 431
- 15.1.2 REVENUE ANALYSIS 431
- 15.1.3 COMPANY SHARE ANALYSIS 432
- 15.1.4 PRODUCT PORTFOLIO 432
- 15.1.5 RECENT DEVELOPMENT 432
- 15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 433
- 15.2.1 COMPANY SNAPSHOT 433
- 15.2.2 REVENUE ANALYSIS 433
- 15.2.3 COMPANY SHARE ANALYSIS 434
- 15.2.4 PRODUCT PORTFOLIO 434
- 15.2.5 RECENT DEVELOPMENTS 434
- 15.3 CERTARA, USA. 435
- 15.3.1 COMPANY SNAPSHOT 435
- 15.3.2 REVENUE ANALYSIS 435
- 15.3.3 COMPANY SHARE ANALYSIS 436
- 15.3.4 PRODUCT PORTFOLIO 436
- 15.3.5 RECENT DEVELOPMENTS 436
- 15.4 SCHRODINGER, INC. 437
- 15.4.1 COMPANY SNAPSHOT 437
- 15.4.2 REVENUE ANALYSIS 437
- 15.4.3 COMPANY SHARE ANALYSIS 438
- 15.4.4 PRODUCT PORTFOLIO 438
- 15.4.5 RECENT DEVELOPMENT 438
- 15.5 CRESSET. 439
- 15.5.1 COMPANY SNAPSHOT 439
- 15.5.2 COMPANY SHARE ANALYSIS 439
- 15.5.3 PRODUCT PORTFOLIO 440
- 15.5.4 RECENT DEVELOPMENTS 440
- 15.6 ACELLERA LTD 441
- 15.6.1 COMPANY SNAPSHOT 441
- 15.6.2 PRODUCT PORTFOLIO 441
- 15.6.3 RECENT DEVELOPMENTS 441
- 15.7 ARGUSLAB 442
- 15.7.1 COMPANY SNAPSHOT 442
- 15.7.2 PRODUCT PORTFOLIO 442
- 15.7.3 RECENT DEVELOPMENT 442
- 15.8 ATOMWISE INC. 443
- 15.8.1 COMPANY SNAPSHOT 443
- 15.8.2 PRODUCT PORTFOLIO 443
- 15.8.3 RECENT DEVELOPMENT 443
- 15.9 BC PLATFORMS 444
- 15.9.1 COMPANY SNAPSHOT 444
- 15.9.2 PRODUCT PORTFOLIO 444
- 15.9.3 RECENT DEVELOPMENTS 445
- 15.10 BIOSOLVEIT GMBH 446
- 15.10.1 COMPANY SNAPSHOT 446

- 15.10.2 PRODUCT PORTFOLIO 446
- 15.10.3 RECENT DEVELOPMENT 446
- 15.11 DOTMATICS 447
- 15.11.1 COMPANY SNAPSHOT 447
- 15.11.2 PRODUCT PORTFOLIO 447
- 15.11.3 RECENT DEVELOPMENTS 448
- 15.12 GENECODE 449
- 15.12.1 COMPANY SNAPSHOT 449
- 15.12.2 PRODUCT PORTFOLIO 449
- 15.12.3 RECENT DEVELOPMENT 449
- 15.13 INSILICOTRIALS TECHNOLOGIES. 450
- 15.13.1 COMPANY SNAPSHOT 450
- 15.13.2 PRODUCT PORTFOLIO 450
- 15.13.3 RECENT DEVELOPMENTS 451
- 15.14 NANOME INC. 452
- 15.14.1 COMPANY SNAPSHOT 452
- 15.14.2 PRODUCT PORTFOLIO 452
- 15.14.3 RECENT DEVELOPMENT 452
- 15.15 OPTIBRIUM, LTD. 453
- 15.15.1 COMPANY SNAPSHOT 453
- 15.15.2 PRODUCT PORTFOLIO 453
- 15.15.3 RECENT DEVELOPMENT 453
- 15.16 PHARMACELERA 454
- 15.16.1 COMPANY SNAPSHOT 454
- 15.16.2 PRODUCT PORTFOLIO 454
- 15.16.3 RECENT DEVELOPMENT 454
- 15.17 SIMULATIONS PLUS. 455
- 15.17.1 COMPANY SNAPSHOT 455
- 15.17.2 REVENUE ANALYSIS 456
- 15.17.3 COMPANY SHARE ANALYSIS 457
- 15.17.4 PRODUCT PORTFOLIO 457
- 15.17.5 RECENT DEVELOPMENT 458
- 15.18 THE SCRIPPS RESEARCH INSTITUTE 459
- 15.18.1 COMPANY SNAPSHOT 459
- 15.18.2 PRODUCT PORTFOLIO 459
- 15.18.3 RECENT DEVELOPMENT 459
- 15.19 VERISIM LIFE, 460
- 15.19.1 COMPANY SNAPSHOT 460
- 15.19.2 PRODUCT PORTFOLIO 460
- 15.19.3 RECENT DEVELOPMENTS 460



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

Global Drug modeling software Market - Industry Trends and Forecast to 2030

Market Report | 2023-06-01 | 468 pages | Data Bridge Market Research

Select license	License			Price
	Single User License			\$4800.00
	Corporate Users License			\$7000.00
			\	/AT
			To	otal
** VAT will be added	at 23% for Polish based companies, ind	ividuals and EU based o	companies who are unable to provid	e a valid EU Va
] D l *		
mail*		Phone*		
irst Name*		Last Name*		
		Last Name*]		
ob title*		Last Name* BU Vat / Tax ID /	/ NIP number*	
ob title* Company Name*			/ NIP number*	
First Name* ob title* Company Name* Address* Zip Code*		EU Vat / Tax ID /	/ NIP number*	
ob title* Company Name* Address*		EU Vat / Tax ID /	/ NIP number*	
ob title* Company Name* Address*		EU Vat / Tax ID / City* Country*		

Scotts International. EU Vat number: PL 6772247784